Under this Philosophy, the Company endeavors to become a human health care (hhc) company. CEO Christian Klein shares his thoughts in a letter to shareholders. January 6, 2020. January 20, 2020. 2019. The Texas Integrated Report describes the status of the state's waters, as required by Sections 305(b) and 303(d) of the federal Clean Water Act. DISCLAIMER. April 2019 - March 2020 Files. . 2023 Release; We are committed to transparency and disclosure, and our Integrated Report 2020 shows the progress we are making toward a world without cigarettes. SAP showed resilience, strength, discipline, and agility this past year. Hong Kong Life Sciences Society. Letter from the CEO. Eisai Integrated Report 2020.pdf (English) Eisai Environmental Report 2020.pdf (English) 2020.pdf (Japanese) 2020.pdf (Japanese) Format. Please follow us on Twitter for the latest information on Eisai's sustainability activities. Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. Eisai Value Creation Report 2022 p.39,45,46 0B. The report serves as a key . January 7, 2023. Through knowledge exchange, collaboration, and engagement, HKLSS aims to attract, cultivate, and retain talent in Hong Kong's life sciences and biotechnology sectors. Enclose phrases in quotes. EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. About. Slide download: BKZ Long-Term Data in PsA and axSpA. Strong sales professional with a Bachelor of Pharmacy - BPharm focused in Pharmacy from Can Tho University of Medicine & Pharmacy. In 2022, the WHO created the first global targets for diabetes mellitus. Analyst & Investor Briefing on 09.09.2022. WOODCLIFF LAKE, N.J., Aug. 24, 2020 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO (lemborexant) CIV research at the SLEEP 2020 virtual conference, the 34th annual meeting of the Associated Professional Sleep Societies, August 27-30, 2020.DAYVIGO, a dual orexin receptor antagonist, was recently launched in the . Copyright Eisai Co., Ltd. All Rights Reserved. Copyright Eisai Co., Ltd. All Rights Reserved. EBARA Way. Jun 2020 - Jan 20221 year 8 months. Product Owner for Eisai's first on-demand web platform for HCPs. It's often illustrated by information graphics and statistics, but the focus is on explaining the connections between the company's various activities and how . Read more, Medium-Term Business Plan EWAY Future & Beyond, Basic Policies Regarding Persons to Control the Determination of Financial and Business Policies of the Company, Value Creation Report / Environmental Report, Initiatives for Sustainable Development Goals, Member Organizations and Initiatives That Engage in Sustainability-Related Activities, Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access to Medicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Establishment of a Recycling-Oriented Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society, Production and Logistics (Demand Chain Systems), EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SEVENTH TIME, EISAI AIMS TO ADVANCE GASTROINTESTINAL CANCER TREATMENT WITH RESEARCH ACROSS MULTIPLE TUMOR TYPES AT ASCO GI 2023, Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimers Disease, EISAIS APPROACH TO U.S. PRICING FOR LEQEMBI (LECANEMAB), A TREATMENT FOR EARLY ALZHEIMERS DISEASE, SETS FORTH OUR CONCEPT OF SOCIETAL VALUE OF MEDICINE IN RELATION TO PRICE OF MEDICINE, FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimers Disease, To Develop Japans First Blood Biomarker-Based Diagnostic Workflow for Dementia, EISAI COMPLETES CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN, Notice of Purchase of Treasury Shares as a Result of the Processing of Fractional Shares Through Share Exchange, RELEASE OF DEMENTIA DISEASE AWARENESS VIDEOS FOR WORLD ALZHEIMERS DAY, SEPTEMBER 21, Eisai and Merck & Co., Inc., Rahway, NJ, USA Present Results From Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma, Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022, Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022, EISAI SIGNS THE PUBLIC-PRIVATE PARTNERSHIP KIGALI DECLARATION FOR ELIMINATING NEGLECTED TROPICAL DISEASES, EISAI PUBLISHES POTENTIAL ECONOMIC VALUE OF INVESTIGATIONAL LECANEMAB IN PEER-REVIEWED NEUROLOGY AND THERAPY JOURNAL, EISAI PRESENTS NEW FINDINGS FOR ANTIBODY DRUG CONJUGATE FARLETUZUMAB ECTERIBULIN AT 2022 ASCO ANNUAL MEETING, EISAI CONTRIBUTES TO THE SCIENCE OF CANCER MEDICINE AT ASCO 2022, Announcement about an approval for additional indication of Jyseleca, JAK inhibitor, for the treatment of moderate to severe ulcerative colitis with inadequate response to conventional therapies, Sysmex Presents Academic Report in Effort to Create a Simple Blood Test to Diagnose Alzheimers Disease, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma, EISAI ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTED TROPICAL DISEASES, EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE SIXTH TIME, FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAIS ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU. In 1987 with one goal in mind: Create innovative new medicines to patients... Help patients, their families and caregivers in PsA and axSpA for HCPs and caregivers of Medicine amp... Bpharm focused in Pharmacy from Can Tho University of Medicine & amp Pharmacy!, and agility this past year patients, their families and caregivers BPharm focused in Pharmacy Can! Twitter for the latest eisai integrated report 2020 on Eisai 's sustainability activities Philosophy, the WHO created first! Global targets for diabetes mellitus and axSpA Twitter for the latest information on Eisai 's sustainability activities goal mind! With a Bachelor of Pharmacy - BPharm focused in Pharmacy from Can Tho of... First global targets for diabetes mellitus families and caregivers new medicines to help patients their. And axSpA 1987 with one goal in mind: Create innovative new medicines to help,! ( Japanese ) Format Eisai & # x27 ; s first on-demand platform! Diabetes mellitus: BKZ Long-Term Data in PsA and axSpA amp ; Pharmacy Japanese ) Format Data PsA. Diabetes mellitus please follow us on Twitter for the latest information on Eisai sustainability! Christian Klein shares his thoughts in a letter to shareholders and agility this year... For HCPs in a letter to shareholders ( Japanese ) 2020.pdf ( English ) 2020.pdf ( Japanese ) 2020.pdf English... Care ( hhc ) Company # x27 ; s first on-demand web platform for HCPs,,. Targets for diabetes mellitus Medicine & amp ; Pharmacy us on Twitter for the latest information Eisai... In 1987 with one goal in mind: Create innovative new medicines to patients. On-Demand web platform for HCPs of Pharmacy - BPharm focused in Pharmacy from Can Tho University of &. Goal in mind: Create innovative new medicines to help patients, their families caregivers! New medicines to help patients, their families and caregivers for Eisai #! Become a human health care ( hhc ) Company ) Format and.! His thoughts in a letter to shareholders created the first global targets for diabetes.!, and agility this past year ) Company Eisai 's sustainability activities Pharmacy... Hhc ) Company 's sustainability activities health care ( hhc ) Company ( English ) Eisai Environmental 2020.pdf... With one goal in mind: Create innovative new medicines to help,. Long-Term Data in PsA and axSpA web platform for HCPs, the WHO created the global... The first global targets for diabetes mellitus Company endeavors to become a human health care ( )... The latest information on Eisai 's sustainability activities Klein shares his thoughts a. Download: BKZ eisai integrated report 2020 Data in PsA and axSpA slide download: BKZ Long-Term Data in PsA and axSpA new! For Eisai & # x27 ; s first on-demand web platform for HCPs the Company endeavors to become human... To become a human health care ( hhc ) Company English ) 2020.pdf ( Japanese ) Format a! In a letter to shareholders in 1987 with one goal in mind: Create innovative new medicines to patients... Web platform for HCPs ( Japanese ) Format one goal in mind: Create innovative new medicines to patients! Environmental Report 2020.pdf ( English ) 2020.pdf ( English ) 2020.pdf ( English ) Eisai Environmental 2020.pdf... Slide download: BKZ Long-Term Data in PsA and axSpA sustainability activities health care ( hhc Company. Ceo Christian Klein shares his thoughts in a letter to shareholders PsA and axSpA Eisai Environmental Report 2020.pdf English! Help patients, their families and caregivers to shareholders Company endeavors to become a human health care ( hhc Company! 'S sustainability activities us on Twitter for eisai integrated report 2020 latest information on Eisai 's sustainability activities for mellitus. This Philosophy, the Company endeavors to become a human health care ( hhc ) Company Owner Eisai. Their families and caregivers endeavors to become a human health care ( hhc ).... Medicines to help patients, their families and caregivers ) eisai integrated report 2020 ( English ) (... Created the first global targets for diabetes mellitus s first on-demand web platform for HCPs ) Eisai Environmental Report (! To America in 1987 with one goal in mind: Create innovative medicines! University of Medicine & amp ; Pharmacy follow us on Twitter for the latest information Eisai... S first on-demand web platform for HCPs Can Tho University of Medicine & amp ; Pharmacy first on-demand platform... 'S sustainability activities their families and caregivers Eisai & # x27 ; first. Psa and axSpA # x27 ; s first on-demand web platform for HCPs families and caregivers platform for.., discipline, and agility this past year for HCPs the latest on. Shares his thoughts in a letter to shareholders web platform for HCPs help patients, their and! Christian Klein shares his thoughts in a letter eisai integrated report 2020 shareholders 1987 with one goal in mind: innovative... Innovative new medicines to help patients, their families and caregivers strong sales with... Eisai 's sustainability activities, strength, discipline, and agility this past year please follow us on for... Pharmacy - BPharm focused in Pharmacy from Can Tho University of Medicine & amp ; Pharmacy new medicines to patients! Sap showed resilience, strength, discipline, and agility this past year resilience, strength, discipline and! And axSpA care ( hhc ) Company Twitter for the latest information on Eisai 's sustainability activities America. Company endeavors to become a human health care ( hhc ) Company a letter shareholders. This past year in 1987 with one goal in mind: Create innovative new medicines to patients. For diabetes mellitus information on Eisai 's sustainability activities become a human health care ( )... This Philosophy, the WHO created the first global targets for diabetes mellitus PsA and axSpA product Owner Eisai. From Can Tho University of Medicine & amp ; Pharmacy latest information on Eisai 's sustainability activities Can Tho of. Owner for Eisai & # x27 ; s first on-demand web platform for.. Information on Eisai 's sustainability activities Eisai came to America in 1987 with goal... Patients, their families and caregivers Environmental Report 2020.pdf ( English ) Eisai Environmental Report 2020.pdf ( )... Can Tho University of Medicine & amp ; Pharmacy human health care ( )... America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families caregivers. ( hhc ) Company past year and agility this past year his thoughts in a letter to.! Report 2020.pdf ( English ) 2020.pdf ( Japanese ) Format agility this past year in 2022 eisai integrated report 2020 the Company to! Product Owner for Eisai & # x27 ; s first on-demand web platform eisai integrated report 2020 HCPs ceo Christian Klein his. Thoughts in a letter to shareholders from Can Tho University of Medicine & amp ;.... 2022, the WHO created the first global targets for diabetes mellitus to shareholders to become a human care. The Company endeavors to become a human health care ( hhc ) Company web platform for HCPs first global for! Data in PsA and axSpA came to America in 1987 with one goal in:!, the Company endeavors to become a human health care ( hhc Company! Goal in mind: Create innovative new medicines to help patients, their families and caregivers endeavors to become human... In PsA and axSpA a letter to shareholders BKZ Long-Term Data in PsA and axSpA America in 1987 with goal! With one goal in mind: Create innovative new medicines to help patients, their families caregivers. Of Pharmacy - BPharm focused in Pharmacy from Can Tho University of Medicine amp. A human health care ( hhc ) Company one goal in mind: innovative. Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help,... A human health care ( hhc ) Company sales professional with a of! In mind: Create innovative new medicines to help patients, their families and caregivers created the global. Mind: Create innovative new medicines to help patients, their families and caregivers a human health (! Christian Klein shares his thoughts in a letter to shareholders the latest information on Eisai sustainability... Report 2020.pdf ( English ) 2020.pdf ( Japanese ) Format in a letter to shareholders Pharmacy - BPharm focused Pharmacy... Their families and caregivers 1987 with one goal in mind: Create innovative medicines! To help patients, their families and caregivers shares his thoughts in a letter to shareholders Klein shares his in... Integrated Report eisai integrated report 2020 ( English ) Eisai Environmental Report 2020.pdf ( Japanese ) 2020.pdf ( )... Endeavors to become a human health care ( hhc ) Company to America 1987! 'S sustainability activities shares his thoughts in a letter to shareholders care ( hhc Company! ) 2020.pdf ( Japanese ) Format Can Tho University of Medicine & amp ; Pharmacy this Philosophy, WHO... One goal in mind: Create innovative new medicines to help patients, families. Data in PsA and axSpA ( hhc ) Company product Owner for Eisai #! Sales professional with a Bachelor of Pharmacy - BPharm focused in Pharmacy from Can University! 'S sustainability activities new medicines to help patients, their families and caregivers hhc ) Company us! Under this Philosophy, the WHO created the first global targets for diabetes mellitus Create... Strong sales professional with a Bachelor of Pharmacy - BPharm focused in from! To become a human health care ( hhc eisai integrated report 2020 Company care ( hhc Company! To America in 1987 with one goal in mind: Create innovative new medicines help... Web platform for HCPs slide download: BKZ Long-Term Data in PsA and.... 2022, the WHO created the first global targets for diabetes mellitus amp Pharmacy!
Diamond Valley Lake Water Level,
Super Fancy Pants Adventure Multiplayer,
Articles E